Skip to content

Impact of dementia risk factors on change in cognitive function and brain structural/functional parameters after brain stimulation in high-risk group of dementia

Impact of amyloid beta retention and brain derived neurotrophic factor Val66Met polymorphism on change in cognitive function and intrinsic functional/structural brain network connectivity after transcranial direct current stimulation in mild cognitive impairment patients: parallel designed, patient-assessor blind, investigator initiated trials

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
CRIS
Registry ID
KCT0006020
Enrollment
90
Registered
2021-03-24
Start date
2019-06-27
Completion date
Unknown
Last updated
2021-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Medical Device : In this double-blind study, patients received 10 tDCS sessions (five times/week for 2 weeks: 10 sessions). The participants were assessed with the CERAD-K neuropsychological battery a

Sponsors

The Catholic University of Korea, Yeouido St. Mary's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: patients with MCI met Peterson’s criteria of (1) memory complaint, corroborated by an informant, (2) objective memory impairment for age, level of education, and sex; (3) essentially preserved general cognitive function; (4) mostly intact functional activities; and (5) no dementia. All patients with MCI had an overall Clinical Dementia Rating of 0.5. Objective memory impairment was defined as a performance score of 1.5 standard deviations (SDs) below the respective age-, education-, and sex-specific normative means on at least one of the four episodic memory tests included in the CERAD-K, that is, WLM, WLR, WLRc, and CR.

Exclusion criteria

Exclusion criteria: We excluded participants with any history of alcoholism, drug abuse, head trauma, or psychiatric disorders, those taking any psychotropic medications (e.g., cholinesterase inhibitors, antidepressants, benzodiazepines, and antipsychotics), those with multiple vascular risk factors, and those with extensive cerebrovascular disease.

Design outcomes

Primary

MeasureTime frame
cognitive function scores;parameters values of brain magnetic resonance imaging

Secondary

MeasureTime frame
cognitive function subdomains scores;functional segregation and integration parameters of brain magnetic resonance imaging

Countries

Korea, Republic of

Contacts

Public ContactDONG WOO KANG

The Catholic University of Korea, Yeouido St. Mary's Hospital

kato7@hanmail.net+82-2-2258-6025

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026